Is regorafenib currently included in the scope of medical insurance reimbursement?

Regorafenib is an oral multi-target tyrosine kinase inhibitor that is widely used in the treatment of a variety of solid tumors. Its mechanism of action covers inhibiting tumor cell proliferation and tumor angiogenesis, targeting multiple signaling pathways such asVEGFR, PDGFR and KIT, etc., making it an important treatment option for patients with advanced malignant tumors. Currently, regorafenib has been officially launched in China and has become a key drug in the treatment plan for some cancer patients. With the improvement of clinical recognition, regorafenib has also been included in the domestic medical insurance directory, which has greatly eased the financial burden of patients and improved the accessibility of medication.

In terms of medical insurance inclusion, regorafenib has been included in the national medical insurance catalog, but the applicable conditions for medical insurance reimbursement are relatively strict. Current medical insurance mainly supports its application in the second-line treatment of hepatocellular carcinoma, the third-line treatment of metastatic colorectal cancer, and the third-line treatment of gastrointestinal stromal tumors. This means that when patients meet the conditions for the above-mentioned conditions and treatment stages, they can enjoy partial reimbursement of drug expenses and reduce their financial burden. The specific reimbursement ratio and process will vary depending on regional policies. It is recommended that patients consult the relevant medical insurance policies and procedures in detail at the hospital pharmacy to obtain the most accurate information.

In terms of price, the market retail price of regorafenib is about 4,000 to 5,000 yuan per box. The specific cost varies slightly depending on different regions and drug purchase channels. Although the price is relatively high, the addition of medical insurance reimbursement effectively reduces the financial pressure on patients. In addition, with the successive launch of generic drugs, the price of regorafenib is expected to be further reduced in the future, improving treatment accessibility for more patients.

In general, regorafenib is a key drug for the treatment of advanced hepatocellular carcinoma, metastatic colorectal cancer and gastrointestinal stromal tumors. Its indications are clear and it has been included in domestic medical insurance, reflecting the country's emphasis on targeted cancer therapy.

Reference materials:https://www.stivarga-us.com/